Skip to main content

BromAc: A new treatment for COVID-19

Project Member(s): Hansbro, P.

Funding or Partner Organisation: Mucpharm Pty Ltd (Mucpaharm Pty Ltd)
Mucpharm Pty Ltd (Mucpaharm Pty Ltd)

Start year: 2020

Summary: Prof. Morris and his team at Mucpharm have developed a formulation consisting of bromelain and acetylcysteine (BromAc®). It is currently being used as a palliative treatment for a rare disease called pseudomyxoma peritonei (where it is administered to patients intraperitoneally). Prof. Morris has shown (in vitro) that BromAc® can disrupt and completely cleave the glycoproteins of the SARS-CoV-2 virus. This meant it prevented the virus from being able to infect cells. BromAc® is ready to be used in a phase 1 human clinical trial to test whether intranasal delivery of BromAc® to patients who have tested positive to SARS-CoV-2 is safe and effective in reducing viral load. However, before this clinical trial can occur Prof. Morris must first test BromAc® in vivo.

FOR Codes: Respiratory System and Diseases (incl. Asthma), Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Clinical health